Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The diabetes drug pioglitazone is associated with increased risk for bladder cancer, according to a large population-based study in The BMJ. Prior research has gone back and forth on whether the thiazolidinedione is indeed associated with increased risk.
Using a U.K. primary care database, researchers studied over 145,000 adults who started treatment with a new diabetes drug class in 2000. During up to 14.5 years' follow-up, roughly 620 patients were diagnosed with bladder cancer. After multivariable adjustment, pioglitazone use was associated with a significant, 63% increased bladder cancer risk relative to no thiazolidinedione use. The risk increase was seen only after 2 years of use.
Pioglitazone was also associated with increased risk relative to rosiglitazone. Rosiglitazone was not associated with increased risk compared with other diabetes drugs.
An editorialist notes that results from most prior research have been consistent with an increase in bladder cancer with pioglitazone, and the current finding "confirms these results."
Comment
LINK(S):
BMJ article (Free)
BMJ editorial (Subscription required)
Background: NEJM Journal Watch General Medicine coverage of 2015 study showing no increase in bladder cancer risk (Free)